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Summary
Background: The catheter lock solutions 2% taurolidine and 0.9% saline are both
used to prevent catheter‐related bloodstream infections (CRBSIs) in home parenteral
nutrition patients.
Aims: To compare the effectiveness and safety of taurolidine and saline.
Methods: This multicentre double‐blinded trial randomly assigned home parenteral
nutrition patients to use either 2% taurolidine or 0.9% saline for 1 year. Patients
were stratified in a new catheter group and a pre‐existing catheter group. Primary
outcome was the rate of CRBSIs/1000 catheter days in the new catheter group and
pre‐existing catheter group, separately.
Results: We randomised 105 patients, of which 102 were analysed as modified
intention‐to‐treat population. In the new catheter group, rates of CRBSIs/1000
catheter days were 0.29 and 1.49 in the taurolidine and saline arm respectively (rel-
ative risk, 0.20; 95% CI, 0.04‐0.71; P = 0.009). In the pre‐existing catheter group,
rates of CRBSIs/1000 catheter days were 0.39 and 1.32 in the taurolidine and saline
arm respectively (relative risk, 0.30; 95% CI, 0.03‐1.82; P = 0.25). Excluding one out-
lier patient in the taurolidine arm, mean costs per patient were $1865 for taurolidine
and $4454 for saline (P = 0.03). Drug‐related adverse events were rare and generally
mild.
Conclusions: In the new catheter group, taurolidine showed a clear decrease in
CRBSI rate. In the pre‐existing catheter group, no superiority of taurolidine could be
demonstrated, most likely due to underpowering. Overall, taurolidine reduced the
risk for CRBSIs by more than four times. Given its favourable safety and cost profile,
taurolidine locking should be considered as an additional strategy to prevent
CRBSIs.
Trial registration: Clinicaltrials.gov, identifier: NCT01826526.
The Handling Editor for this article was Professor Peter Gibson, and it was accepted for
publication after full peer-review.
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1 | INTRODUCTION
Home parenteral nutrition entered the clinical arena in the late
1960s and has since remained the mainstay for the support of
patients with chronic intestinal failure.1-3 This type of nutritional
support requires the presence of a central venous access device
(CVAD), most commonly a catheter, for the supplementation of
nutrients and fluids at home. Despite ongoing technical improve-
ments, catheter‐related bloodstream infections (CRBSIs) remain the
Achilles’ heel of home parenteral nutrition treatment.4 The reported
CRBSI incidence ranges from 0.38 to 2.99 CRBSI per 1000 catheter
days and accounts for approximately 70% of all home parenteral
nutrition‐related hospital admissions.5,6 As such, CRBSIs compromise
venous access and patient survival, and may lead to home parenteral
nutrition failure because of a permanent loss of vascular access.
Strict adherence to aseptic protocols when handling CVADs remains
the key strategy to prevent CRBSIs. The use of anti‐microbial cathe-
ter lock solutions has also been advocated, but the search for the
optimal locking agent remains ongoing.4
Several catheter lock solutions have been studied for their effec-
tiveness in preventing CRBSIs, including antiseptic agents, antibiotics
and anticoagulants. Most catheter lock solutions have been aban-
doned because of side effects, concern about the development of
microbial resistance or mere lack of effect.4 Historically, heparin was
the most commonly used catheter lock solution, also because of the
supposed need for an anticoagulant. However, its use potentially
increases the risk for CRBSIs by promoting intraluminal biofilm for-
mation and is no longer recommended.4,7,8 In 1998, use of the broad‐
spectrum antiseptic agent taurolidine as catheter lock solution was
first described.9 The background for the effect of taurolidine is that
this agent prevents endoluminal biofilm formation by inhibiting
microbial adhesion to the inner surface of the catheter and that it
destroys microbial cell membranes and toxins.10-13 Subsequent stud-
ies and a meta‐analysis confirmed that taurolidine, when compared to
heparin, decreases CRBSI incidence in patients with catheters.14-16
None of these previous studies, however, discriminated between
beneficial effects of taurolidine and/or the detrimental effects of hep-
arin. Currently, 0.9% saline solution is commonly used as an alterna-
tive to taurolidine because of its safety profile and low cost, despite
a lack of evidence from well‐powered studies.4,17 These issues, and
the fact that it remains unclear whether the use of taurolidine should
be restricted to patients with a high risk for CRBSIs, urged us to test
the hypothesis that 2% taurolidine is a superior catheter lock solution
to 0.9% saline in preventing CRBSIs. This hypothesis was tested in
home parenteral nutrition patients who were stratified in two patient
categories. Patients in the first group had a new catheter without any
biofilm, and in this group, the potency of taurolidine to prevent the
development of biofilms (and hence CRBSIs) could be shown.
Patients in the second group had previously experienced CRBSIs and
had a pre‐existing CVAD that possibly had acquired an infection‐pro-
moting biofilm on the inner catheter surface. These patients were at
a higher risk to develop a CRBSI.
2 | METHODS
2.1 | Study oversight
This multicentre, double‐blinded superiority trial was conducted in
six referral centres (Denmark, Israel, Italy, the Netherlands and the
United Kingdom), in which home parenteral nutrition patients were
randomly assigned to use either a catheter lock solution containing
2% taurolidine or 0.9% saline for 1 year. The study design was con-
ceived by the final author and followed close consultation with
members of the Home Artificial Nutrition and Chronic Intestinal
Failure special interest group of the European Society for Clinical
Nutrition and Metabolism. The institutional review board or ethics
committee at each participating centre approved the study protocol.
Geistlich Pharma AG (Wolhusen, Switzerland) provided 2% tauro-
lidine (TauroSept) and 0.9% saline solution, but had no role in the
study design, data analysis or preparation of the manuscript. Acro-
mion GmbH (Frechen, Germany), an independent contract research
organisation, provided data management. Acromion GmbH and the
first author performed the data analyses. The CONSORT guidelines
were followed to report this study.18
2.2 | Participants
Eligible patients were between 18 and 80 years of age and had a
benign underlying disease leading to intestinal failure. Patients
received ≥2 bags per week of nutrition and/or fluids (saline and/or
glucose) over a single‐lumen CVAD. Other eligibility criteria included
an estimated life expectancy ≥1 year and complete understanding of
the nature of the proposed trial.
Patients were stratified into two groups. Patients in the first
group, called “new catheter group”, received a new CVAD (ie without
biofilm) and were either new patients (home parenteral nutrition
naive) or patients who already used home parenteral nutrition. The
latter patients may or may not have had a history of CRBSIs. The sec-
ond group was called “pre-existing catheter group”, and consisted of
supposed “high‐risk” patients, defined as patients having a CVAD that
had already been in place for at least 6 months and thus possibly con-
tained an intraluminal biofilm. In addition, patients had been on home
parenteral nutrition ≥1 year and had previously experienced a CRBSI
rate of ≥0.82/1000 catheter days during their treatment period. The
cut‐off rate of 0.82/1000 catheter days was chosen based on a sys-
tematic review from Dreesen et al who found that the median CRBSI
rate of studies including 50% or more intestinal failure patients with a
benign underlying disease was 0.82 episodes per 1000 catheter
days.19 The pre‐existing catheter group was designed based on expert
opinion, since no exact criteria for high‐risk patients have been
defined in the home parenteral nutrition literature.
Exclusion criteria were antibiotic therapy <2 months prior to trial
inclusion, implantation of antibiotic coated, silver impregnated or
antimicrobial cuff catheters, a current CRBSI, compromised skin
integrity of catheter exit site, use of taurolidine locks in the current
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CVAD, known hypersensitivity to taurolidine and significant cardio-
vascular disease (unstable angina pectoris, acute myocardial infarc-
tion or recent cerebral vascular accident (within 6 weeks), or a
cardiac rhythm, which in the investigators judgement may result in
significant hemodynamic effects). Other exclusion criteria included
clinically significant abnormalities in coagulation requiring interven-
tion, thrombolytic therapy 6 weeks prior to CVAD insertion (80‐
325 mg acetylsalicylic acid daily was acceptable), and concurrent
pregnancy or lactation.
2.3 | Randomisation and blinding
Patients were screened for eligibility during regular outpatient clinical
check‐ups or during hospitalisation. After the local principal investiga-
tor determined eligibility and obtained written informed consent, the
patients were stratified into the new catheter group or pre‐existing
catheter group, and randomised according to a random computer‐per-
muted block scheme (1:1, with block sizes of four patients) to either
2% taurolidine or 0.9% saline by the sponsor in a validated environ-
ment. All vials were identical in appearance, smell and method of
administration. All patients, investigators and site personnel as well as
persons involved in field monitoring, data handling or the conduct of
the trial were blinded to the randomisation data and the trial medica-
tion.
2.4 | Study treatment
Patients or caregivers were instructed according to local training pro-
cedures on how to instil the lock solution at home. The catheter lock
solutions were stored at room temperature. Each time an infusion of
parenteral nutrition or fluids was completed, the CVAD was flushed
with 10 mL sterile physiological saline solution. Subsequently, an
identical vial containing 5 mL 2% taurolidine or 0.9% saline solution
was instilled into the CVAD. The frequency of administration
depended on the patient's parenteral nutrition schedule and ranged
from twice per week to once daily. Patients were seen every
3 months by an investigator during regular outpatient clinic visits or
during unscheduled visits and hospitalisations. At these check‐ups,
CVAD‐related complications, concomitant medication, catheter func-
tion, catheter exit sites and adverse events were assessed. In cases
where a CRBSI was proven during the study, the patient was with-
drawn from the trial after a final visit procedure.
2.5 | Outcomes
A CRBSI was suspected when a patient presented with clinical evi-
dence of systemic infection (ie body temperature >38.5°C or <36°C,
chills, hypotension (systolic blood pressure <90 mm Hg or a
decrease in systolic blood pressure >40 mm Hg), tachycardia (>90
beats per minute), elevated white blood cell count (>12 × 109/L)
and/or C‐reactive protein rise), in the absence of any other apparent
source of infection than the CVAD.4 In this event, paired quantita-
tive or qualitative blood cultures from the CVAD and from a
peripheral vein were taken. A CRBSI was proven when at least one
blood culture was positive from the CVAD or a peripheral vein. In
the absence of positive blood cultures, defervescence after removal
of an implicated catheter from a patient with clinical infectious
symptoms was considered indirect evidence of a CRBSI.4 Blood cul-
tures were performed, analysed and treated according to investiga-
tional site protocols.
The primary outcome was the rate of CRBSIs/1000 catheter days
between taurolidine and saline for the new catheter group and pre‐
existing catheter group, separately. Predefined secondary outcomes
included time to CRBSIs or CVAD removals due to CRBSIs, number
of CVAD removals due to CRBSIs, exit site infections, CVAD occlu-
sions, patient satisfaction with the assigned catheter lock solution
(rated on a scale: not at all satisfied, somewhat unsatisfied, satisfied,
very satisfied), adverse events and cost. The removal of a CVAD due
to a CRBSI was indicated in case of a port abscess, tunnel infection,
in patients with septic shock, or in case of complicated infections,
such as metastatic infections, septic thrombosis or when blood cul-
tures were positive for fungi or virulent bacteria.4 An exit site infec-
tion was defined as a local CVAD infection (local erythema,
induration, tenderness around the CVAD exit site and/or purulent
discharge). A CVAD occlusion was defined as a complete obstruction
of the CVAD lumen (failure to flush or aspirate or the inability to
infuse sufficiently into the CVAD). Patient satisfaction and costs
were assessed at the end of the trial. All other outcomes were
assessed during all scheduled and unscheduled visits.
2.6 | Statistical analysis
The sample size calculation was based on assumptions for the pri-
mary endpoint in the new catheter group. At an 80% power and a
5% significance level, a minimum of 21 patients per arm would be
required to detect a mean numerical difference of 1.5 between the
treatment arms. A standard deviation of 0.3 in the taurolidine arm
and 2 in the saline arm was incorporated, based on the study by Bis-
seling et al, and we assumed a dropout rate of 20%.14 To allow test-
ing for differences in the pre‐existing catheter group, an additional
42 patients were required, resulting in a total of 84 patients. We
aimed to include up to 20 patients from seven participating referral
centres, resulting in a maximum of 140 patients included in the trial.
A statistical analysis plan was finished before unblinding. Origi-
nally, the primary analysis (CRBSI rate between taurolidine and sa‐
line) was tested using a two‐sided Mann‐Whitney U test. However,
after consultation of both an epidemiologist and a statistician, new
insights urged us to submit an amendment (after unblinding) of the
statistical analysis plan and to use a two‐sided Fisher exact test via
the website OpenEpi instead. This website compares incidence rates
by incorporating both events and person‐time.20,21 Of note: use of
the Fisher exact test did not change any of the results and conclu-
sions obtained with the Mann‐Whitney U test (Table S2).
The primary analysis was tested in a modified intention‐to‐treat
population, which included all randomised patients exposed to tau-
rolidine or saline and who had at least one effectiveness assessment
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available. Furthermore, a per‐protocol analysis was performed in
which, in addition to the modified intention‐to‐treat criteria, patients
had to meet the eligibility criteria and complete the trial for planned
visits with complete test results in accordance with all relevant
aspects of the protocol. Safety analyses were based on all ran-
domised patients. Baseline characteristics, effectiveness and safety
measurements were summarised using descriptive statistical meth-
ods. Time‐to‐event endpoints were described by Kaplan‐Meier
curves and were compared using a log‐rank test. Costs were based
on Dutch prices and consisted of catheter lock solution costs and
CRBSI resource use costs (hospitalisations, unscheduled outpatient
clinic consultations, CVAD changes and drug treatment).22,23 The
mean costs per patient were calculated by means of an independent
samples t test after bootstrapping (1000 simulations) with 95% con-
fidence intervals. All other outcomes were analysed using a two‐
sided Fisher exact test. In a post hoc analysis, the results of both
groups were summarised in a combined group analysis. All analyses,
except for the primary analysis, were performed using Statistical
Analysis System software, version 9.4.
3 | RESULTS
3.1 | Study population
Between October 2013 and March 2015, a total of 124 patients were
screened. Following the eligibility criteria, 105 patients were enrolled
in the trial (Figure 1). A total of 102 (97%) patients qualified for the
modified intention‐to‐treat analysis. In the new catheter group, 36 and
35 patients received taurolidine and saline respectively. The median
follow‐up period was 362 days (interquartile range, 201‐369) for tau-
rolidine and 348 days (interquartile range 79‐368) for saline. In the
pre‐existing catheter group, 16 and 15 patients received taurolidine
and saline respectively. The median follow‐up period was 363 days
(interquartile range, 331‐370) for taurolidine and 343 days (interquar-
tile range 119‐370) for saline. Baseline characteristics between tauro-
lidine and saline were similar in each patient group (Table 1). A total of
85 patients were included in the per‐protocol analysis.
3.2 | Outcomes
In the new catheter group, three CRBSIs occurred during 10 248
catheter days in the taurolidine arm, while in the saline arm, 13
CRBSIs occurred in 8708 catheter days, resulting in 0.29 and 1.49
CRBSIs/1000 catheter days for taurolidine and saline respectively
(relative risk, 0.20; 95% CI, 0.04‐0.71; P = 0.009). The cumulative
proportion of CRBSI‐free patients after 1 year was 89% for tauro-
lidine and 43% for saline (P = 0.002) (Figure 2). The remaining sec-
ondary outcomes were non‐significant between taurolidine and
saline. The results of the per‐protocol analysis were generally similar
to the modified intention‐to‐treat analysis (Table S1 and Figure S1).
In the pre‐existing catheter group, two CRBSIs occurred during
5070 catheter days in the taurolidine arm, while in the saline arm,
five CRBSI occurred in 3785 catheter days, resulting in 0.39 and
1.32 CRBSIs/1000 catheter days for taurolidine and saline respec-
tively (relative risk, 0.30; 95% CI, 0.03‐1.82; P = 0.25). The remaining
secondary outcomes were non‐significant between taurolidine and
saline. The results of the per‐protocol analysis were generally similar
to the modified intention‐to‐treat analysis (Table S1 and Figure S1).
In the combined group analyses, five CRBSIs occurred during
15 318 catheter days in the taurolidine arm, while in the saline arm,
18 CRBSIs occurred in 12 493 catheter days, resulting in 0.33 and
1.44 CRBSI/1000 catheter days for taurolidine and saline respectively
(relative risk, 0.23; 95% CI, 0.07‐0.63; P = 0.002) (Table 2). The
cumulative proportion of CRBSI‐free patients after 1 year was 88%
in the taurolidine arm and 49% in the saline arm (P = 0.002) (Fig-
ure 2). The number of patients with a CRBSI‐related catheter removal
was two (4%) in the taurolidine arm and eight (16%) in the saline arm
(P = 0.049). The time to CVAD removal due to CRBSI was signifi-
cantly prolonged in the taurolidine arm (P = 0.02) (Figure 2). The
remaining secondary outcomes were non‐significant between tauro-
lidine and saline. The per‐protocol analyses were generally similar to
the modified intention‐to‐treat analyses (Table S1 and Figure S1).
3.3 | CRBSI‐causing microorganisms
During the study, all CRBSIs were proven by at least one positive
blood culture. In the taurolidine arm, three patients experienced a
monobacterial Gram‐positive CRBSI, one patient a polybacterial
CRBSI and one patient had an episode with a microorganism that
was not specified (Table 3). In the saline arm, six monobacterial
Gram‐positive and eight Gram‐negative CRBSIs occurred. One
patient experienced a polybacterial CRBSI, one patient had an iso-
lated fungaemia and two patients experienced an episode with a
microorganism that was not specified. The CVAD salvage rate in
patients with a CRBSI was 60% for taurolidine and 56% for saline.
3.4 | Adverse events
A total of 71 (68%) patients reported adverse events. Except for
occurrence of CRBSIs, there was no difference in adverse events
between taurolidine and saline (Table 4). CVAD‐related complications
were the most frequently reported adverse event. Drug‐related
adverse events were rare and either mild to moderate. Two patients
deceased in the taurolidine arm, but neither demise was considered
to be drug‐related.
3.5 | Resource use and costs
The mean costs per patient were comparable for taurolidine ($4422)
and saline ($4454) (Table 5). Importantly, however, one patient was
the main cost driver in the taurolidine arm, causing 67% ($153 435)
of all taurolidine costs. This patient was hospitalised for 4 months
because of a disseminated Staphylococcus aureus infection including
endocarditis, during which time a second CRBSI (Candida albicans)
developed, resulting in the patient being admitted to the intensive
care unit. A cost sensitivity analysis, in which was adjusted for this
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single patient, showed a significant cost reduction for taurolidine
($1865, 95% CI, $1016‐2931) compared to saline ($4454, 95% CI,
$2631‐6579) (P = 0.03).
3.6 | Post hoc analysis new catheter group
Of 71 patients included in the new catheter group, 27 (38%) had a
history of at least one CRBSI. Of the remaining 44 patients without
a history of CRBSIs, 13 (72%) in the taurolidine and 13 (50%) in the
saline arm, respectively, were home parenteral nutrition‐naïve at
inclusion. In the group of patients with a history of CRBSIs, three
(17%) in the taurolidine arm and four (44%) in the saline arm experi-
enced a new CRBSI during the study (P = 0.22) (Table 6). Notably, of
44 patients with no record of CRBSIs in the past, none of the
patients in the taurolidine arm experienced a CRBSI, while nine
patients (35%) in the saline arm experienced their first CRBSI during
the study (P = 0.01). Of these nine patients, five patients were home
parenteral nutrition‐naïve.
124 patients were screened
105 underwent randomisation
53 assigned to taurolidine
53 included in
1 excluded from modified
52 included in modified intention-
to-treat analysis
36 in new catheter group
16 in pre-existing catheter group
7 excluded from per-protocol analysis:†
3 received thrombolytic therapy prior to study
1 received thrombolytic therapy prior to study
3 received treatment with systemic
1 had a violation of group allocation
antibiotics prior to study
10 excluded from per-protocol analysis:†
40 included in per-protocol analysis
28 in new catheter group
12 in pre-existing catheter group
45 included in per-protocol analysis
30 in new catheter group
15 in pre-existing catheter group
5 had a violation of group allocation
3 received treatment with systemic
1 had no visit after baseline
antibiotics prior to study
50 included in modified intention-
to-treat analysis
35 in new catheter group
15 in pre-existing catheter group
intention-to-treat analysis:*
1 lost all study medication
due to a fire at home
2 excluded from modified
intention-to-treat analysis:*
1 had an acute respiratory
1 had a perforated colon
distress syndrome
safety analysis
52 included in
safety analysis
37 in new catheter group
16 in pre-existing catheter group
52 assigned to saline
36 in new catheter group
16 in pre-existing catheter group
19 patients excluded from randomisation:
12 refused to participate
7 did not meet in/exclusion criteria:
2 received treatment with systemic antibiotics
2 were hypersensitive to taurolidine
1 used high-dose thrombolytic therapy
1 had elevated C-reactive protein
1 was on short-term home parenteral nutrition
F IGURE 1 Enrollment and follow‐up. *Patients were excluded from the modified intention‐to‐treat analysis because no effectiveness
assessments were available after the baseline visit. †Patients were excluded from the per‐protocol analysis because they either did not meet
eligibility criteria or did not complete the trial before the planned visits with complete test results in accordance with the protocol. Some
patients were excluded from the per‐protocol analysis for more than one reason but were included in only one exclusion category
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4 | DISCUSSION
This study is by far the largest multicentre double‐blind randomised
clinical trial ever performed in the home parenteral nutrition setting,
and the first to demonstrate that 2% taurolidine prevents the devel-
opment of CRBSIs in home parenteral nutrition support, when com-
pared with 0.9% saline. Specifically in the new catheter group, the
CRBSI rate was significantly decreased by taurolidine, and the time
TABLE 1 Baseline characteristics of the new catheter group and the pre‐existing catheter group (modified intention‐to‐treat population)
Characteristic
New catheter group Pre‐existing catheter group
2% taurolidine (n = 36) 0.9% saline (n = 35) 2% taurolidine (n = 16) 0.9% saline (n = 15)
Female—no. of patients (%) 21 (58) 21 (60) 8 (50) 12 (80)
Age—median years (IQR) 59 (51–68) 55 (38‐61) 47 (32–62) 47 (35‐63)
Current medical condition—n (%)
Short‐bowel syndrome 18 (50) 21 (60) 12 (75) 9 (60)
Gastrointestinal motility disorder 14 (39) 9 (26) 4 (25) 4 (27)
Mechanical obstruction 3 (8) 1 (3) 0 (0) 0 (0)
Extensive small bowel mucosal disease 1 (3) 2 (6) 0 (0) 2 (13)
Intestinal fistula 0 (0) 2 (6) 0 (0) 0 (0)
Underlying disease—no. of patients (%)
Crohn's disease 6 (17) 11 (31) 3 (19) 1 (7)
Chronic idiopathic pseudo obstruction 9 (25) 6 (17) 1 (6) 3 (20)
Surgical complications 8 (22) 4 (11) 0 (0) 2 (13)
Mesenteric Ischaemia 5 (14) 7 (20) 1 (6) 0 (0)
Radiation enteritis 2 (6) 2 (6) 1 (6) 1 (7)
Adhesions 0 (0) 1 (3) 2 (13) 2 (13)
Other 6 (17) 4 (11) 8 (50) 6 (40)
Medication—no. of patients (%)
Anticoagulantsa 11 (31) 12 (34) 2 (13) 3 (20)
Immunosuppressantsb 4 (11) 2 (6) 2 (13) 1 (7)
Opiatesc 19 (53) 16 (46) 5 (31) 6 (40)
Medical history—no. of patients (%)
Diabetes 2 (6) 2 (6) 0 (0) 1 (7)
CRBSIs 18 (50) 9 (26) 13 (81)d 12 (80)d
Home parenteral nutrition naïve—no. of patients (%) 13 (36) 13 (37) 0 (0) 0 (0)
Type of venous access device—no. of patients (%)
Hickman catheter 19 (53) 16 (46) 9 (56) 13 (87)
Broviac catheter 11 (31) 11 (31) 2 (13) 0 (0)
Peripheral central venous catheter 2 (6) 2 (6) 4 (25) 1 (7)
Subcutaneous port system 4 (11) 6 (17) 1 (6) 1 (7)
New venous access device—no. of patients (%) 36 (100) 32 (91)e 0 (0) 0 (0)
Type of infusion components—no. of patients (%)
Nutrition 31 (86) 25 (71) 15 (94) 12 (80)
Fluids 5 (14) 10 (29) 1 (6) 3 (20)
Number of infusions per week—Mean ± SD 5.8 (1.6) 6.5 (1.2) 6.3 (1.2) 5.9 (1.2)
CRBSI, catheter‐related bloodstream infection; IQR, interquartile range; SD, standard deviation.
aAnticoagulants comprise all anti‐thrombotic drugs, including acetylsalicylic acid, dipyridamole, phenprocoumon and warfarin.
bImmunosuppressants comprise drugs that suppress or reduce the strength of the body's immune system, such as prednisolone, methotrexate or adali-
mumab.
cOpiates comprise all drugs containing opium or its derivatives, such as codeine, tramadol, oxycodone or buprenorphine.
dSix patients in the pre‐existing catheter group did not experience a CRBSI episode before study enrolment and were improperly included in the pre‐
existing catheter group.
eThree patients in the new catheter group received a CVAD already before study enrolment and were improperly included in the new catheter group.
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to CRBSIs was prolonged. In the pre‐existing catheter group, how-
ever, a statistically significant difference in CRBSI rate could not be
demonstrated for these high‐risk patients. This result is most likely
because of the limited number of patients that could be enrolled into
this group (underpowering). In addition, we cannot rule out that tau-
rolidine might have a lower effectiveness to prevent CRBSIs in the
pre‐existing catheter group because of an already present biofilm
when initiating the taurolidine catheter lock, since such adhesive
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intraluminal layers have been shown to be important precursors for
the development of CRBSIs in long‐term CVADs.10,24 If this were
the case, these findings would underscore the need for strategies—
such as taurolidine locking—that aim to prevent intraluminal biofilm
formation in long‐term CVADs.10-12 In the combined group analysis,
the CRBSI rate was lowered by taurolidine as well, and additional
beneficial effects on (time to) CVAD removals due to CRBSIs were
observed.
It is important to emphasise that adequate catheter care with
strict adherence to aseptic protocols when handling CVADs remains
the key strategy to prevent CRBSIs, whereas catheter locking only
comes second in line in this respect. Our results suggest that, in the
most likely clinical setting, that is, home parenteral nutrition patients
starting locking of a new catheter, taurolidine seems most effective
and as such this agent promises to be an important addition to our
armamentarium to prevent CRBSIs.
When implementing any new preventive strategy, cost‐effective-
ness is an issue on the population level, especially since the back-
ground risk for the development of CRBSIs is a quality indicator for
the care provided by an intestinal failure centre. This implies that to
be cost‐effective in a centre with a very low background risk for
CRBSIs, a substantial number of patients will receive this locking
solution who will never develop an episode of CRBSI, while in those
centres with a high background risk for CRBSIs, cost‐effectiveness
will be easily achieved. At the individual patient level, however, the
prevention of any episode of CRBSI may be crucial in light of the
associated morbidity, risk for loss of options to obtain venous access
and mortality. In this vein, it is also important to mention that so far,
evidence for serious side effects of long‐term catheter locking with
taurolidine in the clinical setting is lacking.25,26 This finding is corrob-
orated by the absence of such deleterious effects when taurolidine
is infused in large volumes (>1 L/d) in humans in the setting of treat-
ment of oncologic diseases.27,28 In light of the trial results, it is our
opinion that there is no reason to withhold taurolidine in any patient
with a new CVAD that is without biofilm for CRBSI prevention.
However, the counterbalance of the previously mentioned issues
and the consideration to implement an effective preventive strategy
in this specific patient category may eventually vary per treating spe-
cialist team. As previously stated, our study results preclude any con-
clusions on the use of taurolidine in high‐risk patients who already
had a CVAD in place, be it due to statistical issues (underpowering)
and/or because of decreased effectiveness in CVADs with a pre‐
existing intraluminal biofilm.
It is often difficult, if not impossible, to discriminate between
CVAD occlusions (either thrombotic or due to parenteral nutrition
components (especially lipids)) on one side, and venous thrombotic
occlusions on the other. In this study, taurolidine showed that no
additional effect on CVAD occlusion rates compared to saline. In
TABLE 2 Outcomes of the modified intention‐to‐treat populationa
New catheter group Pre‐existing catheter group Groups combined
2% taurolidine
(n = 36)
0.9% saline
(n = 35) P value
2% taurolidine
(n = 16)
0.9% saline
(n = 15) P value
2% taurolidine
(n = 52)
0.9% saline
(n = 50) P value
CRBSIs—no. 3 13 2 5 5 18
Total treatment time—
days
Per patient—
median days (IQR)
10 248
362
(201‐369)
8708
348
(79‐368)
5070
363
(331‐370)
3785
343
(119‐370)
15 318
363
(249‐369)
12 493
346
(109‐368)
CRBSIs/1000 catheter
days—(95% CI)
0.29
(0.06‐0.86)
1.49
(0.79‐2.55)
0.009 0.39
(0.04‐1.42)
1.32
(0.43‐3.08)
0.25 0.33
(0.11‐0.76)
1.44
(0.85‐2.23)
0.002
CVAD removal due to
CRBSI—no. (%)
2 (6) 7 (20) 0.08 0 (0) 1 (7) 0.48 2 (4) 8 (16) 0.049
Exit site infection—no.
(%)b
6 (17) 4 (11) 0.74 1 (6) 1 (7) >0.99 7 (14) 5 (10) 0.76
CVAD occlusion—no.
(%)b
2 (6) 1 (3) >0.99 1 (6) 2 (13) 0.60 3 (6) 3 (6) >0.99
Patient satisfaction—no.
(%)b
Not at all satisfied 0 (0) 0 (0) 0.41 0 (0) 0 (0) >0.99 0 (0) 0 (0) 0.80
Somewhat unsatisfied 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Satisfied 9 (25) 6 (17) 6 (38) 6 (40) 15 (29) 12 (24)
Very satisfied 15 (42) 12 (34) 7 (44) 3 (20) 22 (42) 15 (30)
CI, confidence interval; CRBSI, catheter‐related bloodstream infection; CVAD, central venous access device; IQR, interquartile range.
aAll P values were calculated with the use of the Fisher's exact test. CRBSI rates were calculated with the use of the Fisher's exact test from the web-
site OpenEpi.20
bFor exit site infections, data were missing for one patient in the saline arm of the pre‐existing catheter group. For CVAD occlusions, data were missing
for one patient in the saline arm of the pre‐existing catheter group. For patient satisfaction in the new catheter group, data were missing for 12 and 17
patients in the taurolidine and saline groups, respectively. For patient satisfaction in the pre‐existing catheter group, data were missing for three and six
patients in the taurolidine and saline groups respectively.
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addition, a meta‐analysis comparing 1.35% taurolidine and 4% citrate
with heparin did not find any beneficial effects on CVAD occlusion
rates either.15 However, some in vitro and retrospective studies have
reported beneficial effects of taurolidine over heparin, without using
any concomitant anticoagulant protection.11,25,29,30 This decrease in
CVAD occlusions may be explained by a parallel decrease in CRBSIs,
and thus of infection‐induced activation of the coagulation system,
rather than anti‐coagulant properties of taurolidine.
Despite prolonged use of taurolidine, some patients still devel-
oped CRBSIs. One reason might be breaches or non‐compliance of
patients or caregivers to antiseptic CVAD care protocols. Another
TABLE 3 Microorganisms causing catheter‐related bloodstream
infectionsa
2% taurolidine
(n = 52)
0.9% saline
(n = 50) P value
Infection type – no. of CRBSIs
Monobacterial bloodstream
infection
3 14 0.21
Gram‐positive – % 3 (100) 6 (43)
Gram‐negative – % 0 (0) 8 (57)
Polybacterial bloodstream
infectionb
1 1
Isolated fungemia 0 1
Unknownc 1 2
Total 5 18
Gram–positive – no. of microorganismsd
Bacillus cereus 0 1
Staphylococcus aureus 1 2
Staphylococcus epidermidis 1 4
Streptococcus salivarius 1 0
Species not specified 1 0
Total 4 7
Gram–negative – no. of microorganismse
Acinetobacter ursingii 0 1
Citrobacter koseri 0 1
Klebsiella oxytoca 0 1
Klebsiella pneumonia 0 2
Morganella morganii 0 1
Neiserna elongate 1 0
Stenotrophomonas maltophilia 0 1
Serratia marcescens 0 1
Species not specified 0 2
Total 1 10
Fungemia—no. of microorganisms
Candida albicans 0 1
CRBSI, catheter‐related bloodstream infection.
aP value was calculated with the use of Fisher's exact test.
bIn the taurolidine and saline group, respectively two (Streptococcus sali-
varius and Neiserna elongata) and three (Acinetobacter ursingii, Stenotro-
phomonas maltophilia and Staphylococcus epidermidis) microorganisms
were grown from one blood culture.
cA positive blood culture was reported; however, the microorganism
involved was not documented.
dGram–positive species cultured from both monobacterial and polybacte-
rial blood cultures.
eGram–negative species cultured from both monobacterial and polybacte-
rial blood cultures.
TABLE 4 Clinical adverse events (safety analysis)a
2% taurolidine
(n = 53)
0.9% saline
(n = 52)
P valueNo. of patients – (%)
Adverse events
Patients with ≥1 adverse
events (≥5% of patients)
32 (60) 39 (75) 0.14
Abdominal pain 4 (8) 4 (8) >0.99
Catheter dislocation 2 (4) 3 (6) 0.68
Catheter exit site infection 5 (9) 4 (8) >0.99
CVAD occlusion 2 (4) 5 (10) 0.27
CRBSI 5 (9) 18 (35) 0.002
Pneumonia 4 (8) 1 (2) 0.36
Pyrexia 1 (2) 4 (8) 0.21
Urinary tract infection 5 (9) 5 (10) >0.99
Patients with drug‐related
adverse events (Intensity)
2 (4) 2 (4) >0.99
Dysgeusia (moderate) 1 0
Dizziness (moderate) 1 0
Erythema to catheter
exit site (moderate)
1 0
Flushing (mild) 0 1
Reduced catheter
patency (mild)
0 1
Serious adverse events
Patients with ≥1 serious
adverse event (≥2% of
patients)
23 (43) 34 (65) 0.03
Abdominal pain 1 (2) 2 (4) 0.62
Catheter dislocation 2 (4) 3 (6) 0.68
Catheter exit site
infection
4 (8) 3 (6) >0.99
CVAD occlusion 0 (0) 3 (6) 0.12
CRBSI 4 (8) 18 (35) 0.001
Pneumonia 4 (8) 0 (0) 0.12
Patients with serious
drug‐related adverse event
0 (0) 0 (0) >0.99
Discontinuation of treatment
due to adverse event
11 (21) 23 (44) 0.02
Death 2 (4) 0 (0) 0.50
Euthanasia after bowel
obstruction
1 0
Ruptured abdominal
aneurysm
1 0
CRBSI, catheter‐related bloodstream infection; CVAD, central venous
access device.
aP values were calculated with the use of Fisher's exact test.
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reason could be selective growth of microorganisms with a pheno-
typic adaptation to taurolidine. This matter was previously addressed
when we evaluated microbicidal concentrations of taurolidine in bac-
terial strains that caused CRBSIs in a heparin‐controlled trial but
TABLE 5 Cost and sensitivity analysis of modified intention‐to‐treat population
2% taurolidine (n = 52) 0.9% saline (n = 50) P value
Catheter lock solution costs
Study treatment—days
CLS price per daya
Total cost of catheter lock solution—USD
Mean cost of catheter lock solution per patient—(95% CI)b
15 318
3.48
45 949
884 (772‐998)
12 493
0.70
7879
158 (131‐183)
<0.001
Resource use
Hospital admissions due to CRBSIs—no.
Total hospital admission days
Ward
Intensive care unit
Total cost of hospital admissions—USDc
Mean cost of hospital admissions per patient—(95% CI)b
5
161
145
16
122 701
2360 (42‐6810)
18
229
229
0
160 970
3219 (1865‐4798)
0.70
Outpatient clinic consultations—no.
Total cost of consultations—USDc
Mean cost of consultations per patient—(95% CI)b
0
0
0 (0‐0)
1
178
4 (0‐12)
0.12
Antimicrobial treatment—days
Cost of drug treatment—USDd
Mean cost of drug treatment per patient—(95% CI)b
325
53 339
1026 (12‐3329)
423
32 423
648 (176‐1376)
0.71
CVAD changes
Cost of CVAD changes—USDe
Mean cost of CVAD changes per patient—(95% CI)b
3
7974
153 (0‐412)
8
21 264
425 (170‐702)
0.12
Total costs—USD
Costs per treatment day—USD
Costs per treatment year—USD
Total costs per patient in USD—mean (95% CI)b
229 963
15.0
5491
4422 (978‐11 350)
222 715
17.8
6507
4454 (2631‐6579)
>0.99
Sensitivity analysisf
Total costs—USD
Costs per treatment day—USD
Costs per treatment year—USD
Total costs per patient in USD—mean (95% CI)b
96 994
6.3
2311
1865 (1016‐2931)
222 715
17.8
6507
4454 (2631‐6579)
0.03
CI, confidence interval; CRBSI, catheter‐related bloodstream infection; CVAD, central venous access device; USD, United States dollar.
aPrice of 2% taurolidine (TauroSept) per day in the Netherlands: $3.48. Price of 0.9% saline solution per day: $0.70.
bCosts (USD) were compared using an independent samples t test after bootstrapping (1000 simulations).
cHospital admission and outpatient clinic consultation prices are based on the Dutch guidelines for conducting economic evaluations in healthcare
(2016) from Zorginstituut Nederland (The Netherlands Healthcare Institute).22 Price of 1‐day ward admission: $703. Price of 1‐day intensive care unit:
$1299. Price of outpatient clinic consultation: $178.
dCRBSI drug treatment prices are based on medicijnkosten.nl (2016) from Zorginstituut Nederland (The Netherlands Healthcare Institute).23
ePrice of CVAD change in the Netherlands (including costs CVAD, operation room, surgeon, anaesthetics): $2658.
fOne patient was a major outlier in the taurolidine arm with 67% ($153 435) of the total taurolidine costs. In a sensitivity analysis, the patients costs
were adjusted by winsorising (the original value was replaced by the nearest value of an observation not seriously suspect) the hospital admission
($14 059 instead of $96 693) and drug treatment costs ($785 instead of $51 120) in the taurolidine arm.
TABLE 6 Post hoc analysis of the new catheter groupa
History of CRBSIs No history of CRBSIs
2% Taurolidine (n = 18) 0.9% Saline (n = 9) P value 2% Taurolidine (n = 18) 0.9% Saline (n = 26) P value
CRBSIs—no. 3 4 0 9
Total treatment time—days 4992 1996 5256 6712
CRBSIs/1000 catheter
days—(95% CI)
0.60 (0.12‐1.76) 2.00 (0.54‐5.13) 0.22 0 (0‐0) 1.34 (0.61‐2.55) 0.01
CI, confidence interval; CRBSI, catheter‐related bloodstream infection.
aP values were calculated with the use of Fisher's exact test from the website OpenEpi.20
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found no evidence for altered bacterial susceptibility to tauroli-
dine.14,31 This was not unexpected, given taurolidines’ non‐specific
chemical aseptic mode of action. To date, no microbial resistance to
taurolidine has been reported.11,15,32
The CVAD salvage rate of 60% in patients with a CRBSI was
similar in both arms and is comparable to rates observed in previous
studies (55%‐80%).6,33,34 With regard to the microbial pathogens
leading to CRBSIs, several cohort studies reported a preponderance
of infections caused by Gram‐positive (60%‐80%) over Gram‐nega-
tive bacteria (20%‐40%).4,19,35,36 One meta‐analysis showed that the
use of taurolidine significantly decreased CRBSIs caused by Gram‐
negative bacteria, whereas CRBSIs from Gram‐positive organisms did
not change.15 In this trial, there was no difference in the type of
pathogens leading to CRBSIs between taurolidine and saline.
Although taurolidine showed a clear beneficial effect in terms of
CRBSI prevention in the new catheter group and the groups com-
bined, patient satisfaction did not differ between taurolidine and sal-
ine, and was high in both arms. The low number of drug‐related
adverse events in both groups may be a likely explanation for this.
The use of taurolidine increased catheter lock solution costs
compared with saline, but the mean total costs per patient were sim-
ilar between the two treatment arms. The increase in taurolidine
costs was offset by the obviously much higher CRBSI resource use
(more hospital admissions, CRBSI drug treatment and CVAD
changes) in the saline arm. However, if the extraordinary high costs
in one patient in the taurolidine arm (who was responsible for two‐
thirds of all costs in this arm) were adjusted in a sensitivity cost anal-
ysis, taurolidine showed a decrease in costs per patient.
The strengths of this trial include its design with a low risk of
bias, owing to the (patient and investigator) blinding and randomly
allocated treatment assignments. The multicentre design in combina-
tion with only few major exclusion criteria ensured that the majority
of screened patients were included and thus provided a good repre-
sentation of a typical chronic intestinal failure population with
benign underlying intestinal failure.4,34 Another strength is the prag-
matic design of this trial, where routine daily practice remained
unchanged as much as possible; for example, patients or caregivers
managed the venous catheter and infusion pump at home and
instilled the catheter lock solutions according to local training proce-
dures.
A clear limitation of this trial is the inclusion of the pre‐existing
catheter group. The inclusion was partly hampered by participation
of only six instead of seven centres due to local administrative
issues, and because one of the six remaining centres was unable to
include high‐risk patients due to previous use of taurolidine in the
CVADs. This latter group, in whom any beneficial effect of a CRBSI‐
preventing measure might be expected to be most noticeable, was
based on expert opinion, since no strict criteria for high‐risk patients
have been defined in the home parenteral nutrition literature. The
assumptions on which this group was based may have been too
strict (eg CVADs ≥6 months in place and no antibiotic therapy
<2 months prior to trial inclusion), resulting in a lower than expected
number of high‐risk patients in the study, and subsequently an
underpowered group. In addition, some patients in the pre‐existing
catheter group were improperly included as these patients did not
have CRBSIs in their medical history and therefore did not meet the
criteria for being a high‐risk patient. A second limitation of our study
is that it was performed against the background of a certain
infectious complication rate. As mentioned, this does not necessarily
prove that the cost‐effectiveness of the strategy to use taurolidine
also pertains to centres with an extremely low CRBSI rate.
Our study outcomes may be relevant for other fields (haemodial-
ysis, oncology) where reliable venous access is paramount. Apart
from the 2% taurolidine formulation that was used in this study, var-
ious other combinations of 1.35% taurolidine and anticoagulants (ci-
trate, heparin or urokinase) are available. These agents are intended
for use in areas with a risk for thrombotic occlusion, such as
haemodialysis, where blood necessarily enters the catheter. In the
absence of adequately powered studies comparing taurolidine for-
mulations with and without concomitant anticoagulants, we can only
speculate about their effectiveness in the setting of home parenteral
nutrition.
Future research should focus on additional strategies to minimise
CRBSI rates, apart from patient and caregiver training in catheter
handling, including optimisation of (taurolidine‐containing) locking
formulations and its selection in subgroups of patients with a higher
risk for CBRSIs, and the use of devices such as antimicrobial catheter
caps.37
In conclusion, using 2% taurolidine as catheter lock solution
decreases the risk for CRBSIs in home parenteral nutrition patients
with a new catheter compared with 0.9% saline. It remains unclear
whether this also applies for patients with a supposed high CRBSI
risk who already have had a catheter in place. Given its favourable
safety and cost profile, our study supports the use of 2% taurolidine
locking for CRBSI prevention in home parenteral nutrition care.
ACKNOWLEDGEMENTS
We thank the research nurses, investigators and administrative assis-
tants of the participating centres for their help with participant
recruitment and data collection; the members of the data safety
monitoring committee, and the patients and their partners who par-
ticipated in this study.
Declaration of personal interests: All authors have completed the
ICMJE uniform disclosure at www.icmje.org/coi_disclosure.pdf and
declare: financial support for the submitted work from Geistlich
Pharma AG; GW reports grants from Fresenius Kabi, Baxter interna-
tional and BBraun Medical outside the submitted work. GW is con-
sultant for Shire. ST reports a grant from TauroPharm GmbH.
AUTHORSHIP
Guarantor of the article: GW.
Author contributions: GW conceived and designed the study, pro-
duced the protocol and managed the study. FR, GW, HR, LP, LV,
MT, PJ, PS and ST acquired the data. Acromion GmbH and YW
420 | WOUTERS ET AL.
analysed the data. YW produced the first complete draft and
updated subsequent drafts. GW, HR, LP, LV, MT, PJ, PS, ST and YW
interpreted the data, critically revised the manuscript and approved
all drafts and the authorship list.
ETHICS APPROVAL
This study was approved by the research ethics committee of the
Radboudumc in Nijmegen, the Netherlands (reference number
NL40910.091.12) and by the board of directors and/or the research
ethics committee of each of the participating hospitals. The study
was conducted in accordance with Good Clinical Practice guidelines
and the Declaration of Helsinki.
DATA SHARING
The full data set is available from the corresponding author at
Yannick.Wouters@radboudumc.nl on reasonable request. Consent
was not obtained for data sharing, but the presented data are anon-
ymised and risk of identification is low.
TRANSPARENCY
The lead author (GW) affirms that the manuscript is an honest, accu-
rate and transparent account of the study being reported; that no
important aspects of the study have been omitted; and that any dis-
crepancies from the study as planned (and, if relevant, registered)
have been explained. All authors had full access to all of the data in
the study and take responsibility for the integrity of the data and
the accuracy of the data analysis. All authors operated independently
from the funder. The lead author takes full responsibility for the
integrity of the data, the accuracy of the data analysis and had final
responsibility for the decision to submit for publication.
ORCID
Y. Wouters http://orcid.org/0000-0002-5822-0255
REFERENCES
1. Scribner BH, Cole JJ, Christopher TG, et al. Long‐term total par-
enteral nutrition. The concept of an artificial gut. JAMA 1970;212:
457‐463.
2. Shils ME, Wright WL, Turnbull A, et al. Long‐term parenteral nutri-
tion through an external arteriovenous shunt. N Engl J Med.
1970;283:341‐344.
3. Pironi L, Arends J, Baxter J, et al. ESPEN endorsed recommenda-
tions. Definition and classification of intestinal failure in adults. Clin
Nutr. 2015;34:171‐180.
4. Pironi L, Arends J, Bozzetti F, et al. ESPEN guidelines on chronic
intestinal failure in adults. Clin Nutr. 2016;35:247‐307.
5. Wanten G, Calder PC, Forbes A. Managing adult patients who need
home parenteral nutrition. BMJ. 2011;342:d1447.
6. Dibb MJ, Abraham A, Chadwick PR, et al. Central venous catheter
salvage in home parenteral nutrition catheter‐related bloodstream
infections: long‐term safety and efficacy data. JPEN J Parenter Enteral
Nutr. 2016;40:699‐704.
7. Shanks RM, Donegan NP, Graber ML, et al. Heparin stimulates Staphy-
lococcus aureus biofilm formation. Infect Immun. 2005;73:4596‐4606.
8. Allon M. Prophylaxis against dialysis catheter‐related bacteremia: a
glimmer of hope. Am J Kidney Dis. 2008;51:165‐168.
9. Jurewitsch B, Lee T, Park J, et al. Taurolidine 2% as an antimicrobial
lock solution for prevention of recurrent catheter‐related blood-
stream infections. JPEN J Parenter Enteral Nutr 1998;22:242‐244.
10. Handrup MM, Fuursted K, Funch P, et al. Biofilm formation in long‐
term central venous catheters in children with cancer: a randomized
controlled open‐labelled trial of taurolidine versus heparin. APMIS.
2012;120:794‐801.
11. Shah CB, Mittelman MW, Costerton JW, et al. Antimicrobial activity
of a novel catheter lock solution. Antimicrob Agents Chemother
2002;46:1674‐1679.
12. Luther MK, Mermel LA, LaPlante KL. Comparison of ML8‐X10 (a
prototype oil‐in‐water micro‐emulsion based on a novel free fatty
acid), taurolidine/citrate/heparin and vancomycin/heparin antimicro-
bial lock solutions in the eradication of biofilm‐producing staphylo-
cocci from central venous catheters. J Antimicrob Chemother.
2014;69:3263‐3267.
13. Calabresi P, Goulette FA, Darnowski JW. Taurolidine: cytotoxic and
mechanistic evaluation of a novel antineoplastic agent. Can Res
2001;61:6816‐6821.
14. Bisseling TM, Willems MC, Versleijen MW, et al. Taurolidine lock is
highly effective in preventing catheter‐related bloodstream infections
in patients on home parenteral nutrition: a heparin‐controlled
prospective trial. Clin Nutr. 2010;29:464‐468. https://doi.org/10.
1016/j.clnu.2009.12.005
15. Liu Y, Zhang AQ, Cao L, et al. Taurolidine lock solutions for the pre-
vention of catheter‐related bloodstream infections: a systematic
review and meta‐analysis of randomized controlled trials. PLoS ONE.
2013;8:e79417.
16. Tribler S, Brandt CF, Petersen AH, et al. Taurolidine‐citrate‐heparin
lock reduces catheter‐related bloodstream infections in intestinal
failure patients dependent on home parenteral support: a random-
ized, placebo‐controlled trial. Am J Clin Nutr. 2017;106:839‐848.
17. Klek S, Szczepanek K, Hermanowicz A, et al. Taurolidine lock in
home parenteral nutrition in adults: results from an open‐label ran-
domized controlled clinical trial. JPEN J Parenter Enteral Nutr.
2015;39:331‐335.
18. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement:
updated guidelines for reporting parallel group randomised trials.
BMJ. 2010;340:c332.
19. Dreesen M, Foulon V, Spriet I, et al. Epidemiology of catheter‐
related infections in adult patients receiving home parenteral nutri-
tion: a systematic review. Clin Nutr. 2013;32:16‐26.
20. OpenEpi.com. http://www.openepi.com/PersonTime2/PersonTime2.
htm.
21. Rijksinstituut voor Volksgezondheid en Milieu (RIVM). http://www.
rivm.nl/Onderwerpen/P/PREZIES/Infectiecijfers_betrouwbaar_gebruike
n/Statistische_betrouwbaarheid_van_infectiecijfers.
22. Dutch guidelines for conducting economic evaluations in healthcare:
Zorginstituut Nederland; 2016 [updated 29-02-2016]. https://
www.zorginstituutnederland.nl/over-ons/publicaties/publicatie/2016/
02/29/richtlijn-voor-het-uitvoeren-van-economische-evaluaties-in-de-
gezondheidszorg.
23. Medicijnkosten.nl: Zorginstituut Nederland; 2016 [updated 01-04-
2017]. www.medicijnkosten.nl.
24. Raad I, Costerton W, Sabharwal U, et al. Ultrastructural analysis of
indwelling vascular catheters: a quantitative relationship between
WOUTERS ET AL. | 421
luminal colonization and duration of placement. J Infect Dis
1993;168:400‐407.
25. Olthof E, Versleijen M, Huisman-De Waal G, et al. Taurolidine lock is
superior to heparin lock in the prevention of catheter related blood-
stream infections and occlusions. Clin Nutr. 2014;33:S104‐S105.
26. Lambe C, Poisson C, Talbotec C, et al. Strategies to Reduce Cathe-
ter‐Related Bloodstream Infections in Pediatric Patients Receiving
Home Parenteral Nutrition: The Efficacy of Taurolidine‐Citrate Pro-
phylactic‐Locking. JPEN Journal of parenteral and enteral nutrition.
2018; https://doi.org/10.1002/jpen.1043.
27. Stendel R, Scheurer L, Schlatterer K, et al. Pharmacokinetics of tau-
rolidine following repeated intravenous infusions measured by
HPLC‐ESI‐MS/MS of the derivatives taurultame and taurinamide in
glioblastoma patients. Clin Pharmacokinet 2007;46:513‐524.
28. Braumann C, Winkler G, Rogalla P, et al. Prevention of disease pro-
gression in a patient with a gastric cancer‐re‐recurrence. Outcome
after intravenous treatment with the novel antineoplastic agent tau-
rolidine. Report of a case. World J Surg Oncol. 2006;4:34.
29. Reinmuller J. [The influence of taurolidine on physiological and
pathological blood coagulation and implications for its use]. Zentralbl
Chir. 1999;124 (Suppl 4):13‐18.
30. Kaptanoglu L, Kucuk HF, Colak E, et al. The effect of taurolidine on
experimental thrombus formation. Eur J Pharmacol. 2008;578:238‐241.
31. Olthof ED, Rentenaar RJ, Rijs AJ, et al. Absence of microbial adapta-
tion to taurolidine in patients on home parenteral nutrition who
develop catheter related bloodstream infections and use taurolidine
locks. Clin Nutr. 2013;32:538‐542.
32. Chu HP, Brind J, Tomar R, et al. Significant reduction in central
venous catheter‐related bloodstream infections in children on HPN
after starting treatment with taurolidine line lock. J Pediatr Gastroen-
terol Nutr. 2012;55:403‐407.
33. Clare A, Teubner A, Shaffer JL. What information should lead to a
suspicion of catheter sepsis in HPN? Clin Nutr. 2008;27:552‐556.
34. Brandt CF, Tribler S, Hvistendahl M, et al. Home parenteral nutrition
in adult patients with chronic intestinal failure: catheter‐related com-
plications over 4 decades at the main Danish Tertiary Referral Cen-
ter. JPEN J Parenter Enteral Nutr. 2018;42:95‐103.
35. Santarpia L, Alfonsi L, Tiseo D, et al. Central venous catheter infec-
tions and antibiotic therapy during long‐term home parenteral nutri-
tion: an 11‐year follow‐up study. JPEN J Parenter Enteral Nutr.
2010;34:254‐262.
36. Tribler S, Brandt CF, Hvistendahl M, et al. Catheter‐related blood-
stream infections in adults receiving home parenteral nutrition. JPEN
J Parenter Enteral Nutr. 2017;148607116686290.
37. Voor In ‘t Holt AF, Helder OK, Vos MC, et al. Antiseptic barrier cap
effective in reducing central line‐associated bloodstream infections:
a systematic review and meta‐analysis. Int J Nurs Stud 2017;69:
34‐40.
SUPPORTING INFORMATION
Additional supporting information will be found online in the
Supporting Information section at the end of the article.
How to cite this article: Wouters Y, Theilla M, Singer P, et al.
Randomised clinical trial: 2% taurolidine versus 0.9% saline
locking in patients on home parenteral nutrition. Aliment
Pharmacol Ther. 2018;48:410–422. https://doi.org/10.1111/
apt.14904
422 | WOUTERS ET AL.
